All Stories
Follow
Subscribe to Medigene AG

Medigene AG

ots Ad hoc-Service: MediGene AG <DE0005020903> MediGene AG Expects Dismissal of its Lawsuit against Loyola University of Chicago and Medimmune, Inc.

Martinsried (ots Ad hoc-Service) -

Ad hoc-announcement edited and sent by DGAP. The sender is solely
responsible for the contents of this announcement.
MediGene AG, a German biotech
company listed on the Neuer Markt at the Frankfurt Stock Exchange,
today announced that the United States District Court in Chicago has
indicated it will enter judgment against MediGene on or about April
4, 2001, on MediGene's lawsuit, filed in 1998, against Loyola
University of Chicago, MedImmune, Inc., a United States biotech
company, and an individual defendant. MediGene is reviewing the legal
consequences of the expected judgment against it and considering an
appeal to the United Stales Court of Appeals. The dispute concerns
the CVLP technology, a method for the creation of virus-like
particles that MediGene has been developing for the potential
treatment of HPV-induced tumors.
MediGene's lawsuit against Loyola sought to determine ownership of
certain patents relating to the CVLP technology and alleged the
breach of a Memorandum of Understanding between Loyola and MediGene
regarding rights under those patents. MediGene's lawsuit also charged
MedImmune and a further defendant with tortious interference with the
Memorandum of Understanding, breach of a material transfer agreement
between MediGene and MedImmune, and tortious interference with
MediGene's prospective economic advantage. Loyola and MedIummune
rejected the charges and filed counterclaims against MediGene, which
MediGene has denied. The Court dismissed MediGene's secondary claims
for damages and injunctive relief based on the Memorandum of
Understanding on December 19, 2000. In hearings held in mid-March
2001 regarding Medigene's primary claims to ownership of the disputed
patents, the Court orally stated that it would grant Loyola's and
MedImmune's motions for summary judgment on all counts of MediGene's
claims. The Court has not indicated when it will rule on various
counterclaims brought by Loyola and MedImmune against MediGene.
The CVLP technology is one of MediGene's five product candidate
programs and is the basis for a product candidate in clinical Phase
I/II. MediGene has four further product candidates in clinical
development, including one each in clinical Phase III, clinical Phase
II, clinical Phase I/II, and one that has completed clinical Phase
I/II.
MediGene and Schering AG, with whom MediGene has a collaboration
agreement relating to the CVLP technology in dispute, expect ongoing
settlement negotiations with the defendants to continue.
For further information please contact:
MediGene AG email:  investor@medigene.de fax: ++49 -89-89 56 32-20
Christine Bohner, Public Relations phone: ++49 -89-89 56 32-16
Michael Nettersheim, Investor Relations phone: ++49 -89-89 56 32-46
end of ad hoc announcement, (c) DGAP 23.03.2001
WKN: 502090; Index: NEMAX- 50 Listed: Neuer Markt in Frankfurt;
Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München
und Stuttgart
End
 Internet: http://recherche.newsaktuell.de

Original content of: Medigene AG, transmitted by news aktuell